Lexeo Therapeutics, Inc. (LXEO)

Market Cap	540.84M +181.9%
Revenue (ttm)	n/a
Net Income	-104.97M
EPS	-2.45
Shares Out	72.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	881,519
Open	7.50
Previous Close	7.57
Day's Range	7.12 - 7.64
52-Week Range	1.45 - 10.99
Beta	1.77
Analysts	Strong Buy
Price Target	18.60 (+151.01%)
Earnings Date	Nov 5, 2025

About LXEO

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 3, 2023
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: LXEO
• Website: https://www.lexeotx.com

Analyst Summary

According to 10 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $18.6, which is an increase of 151.01% from the latest price.

Price Target

$18.6

(151.01% upside)

Analyst Consensus: Strong Buy